Furthermore, EGFRm circulating tumor DNA (ct-DNA) clearance on treatment (around cycle 3/4) predicted longer PFS in patients with detectable baseline ctDNA, while nearly half of the patients developed acquired resistance, mainly involving MET, EGFR, and KRAS alterations. The gene discussed is MET; the disease is neoplasm.